Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to Keytruda (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
